Chris Schott
Stock Analyst at JP Morgan
(3.90)
# 625
Out of 5,053 analysts
147
Total ratings
64.36%
Success rate
5.18%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Maintains: Overweight | $26 → $28 | $24.26 | +15.42% | 19 | Nov 6, 2025 | |
| PRGO Perrigo Company | Downgrades: Neutral | $32 → $20 | $14.25 | +40.35% | 13 | Nov 6, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $230 → $200 | $119.79 | +66.96% | 3 | Nov 5, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $675 → $775 | $709.59 | +9.22% | 9 | Nov 4, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $250 → $260 | $218.71 | +18.88% | 4 | Nov 3, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $145 → $150 | $118.15 | +26.96% | 8 | Oct 31, 2025 | |
| ELAN Elanco Animal Health | Upgrades: Overweight | $18 → $24 | $22.27 | +7.77% | 4 | Oct 7, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,100 → $1,050 | $966.64 | +8.62% | 22 | Sep 16, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $12 → $14 | $11.48 | +21.95% | 3 | Sep 16, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $950 → $800 | $654.74 | +22.19% | 8 | Jun 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $185 → $175 | $156.26 | +11.99% | 4 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $18 → $20 | $7.71 | +159.40% | 2 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $42 | $38.54 | +8.98% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $270 | $323.66 | -16.58% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $34 | $24.39 | +39.40% | 10 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $86.75 | +44.09% | 7 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $14 | $10.17 | +37.66% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $1.26 | +773.02% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.40 | - | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $78 | $47.26 | +65.04% | 7 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $700 → $950 | $0.73 | +129,858.96% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.35 | - | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $23.07 | +116.73% | 3 | Nov 2, 2018 |
Teva Pharmaceutical Industries
Nov 6, 2025
Maintains: Overweight
Price Target: $26 → $28
Current: $24.26
Upside: +15.42%
Perrigo Company
Nov 6, 2025
Downgrades: Neutral
Price Target: $32 → $20
Current: $14.25
Upside: +40.35%
Zoetis
Nov 5, 2025
Maintains: Overweight
Price Target: $230 → $200
Current: $119.79
Upside: +66.96%
IDEXX Laboratories
Nov 4, 2025
Maintains: Overweight
Price Target: $675 → $775
Current: $709.59
Upside: +9.22%
AbbVie
Nov 3, 2025
Maintains: Overweight
Price Target: $250 → $260
Current: $218.71
Upside: +18.88%
Gilead Sciences
Oct 31, 2025
Maintains: Overweight
Price Target: $145 → $150
Current: $118.15
Upside: +26.96%
Elanco Animal Health
Oct 7, 2025
Upgrades: Overweight
Price Target: $18 → $24
Current: $22.27
Upside: +7.77%
Eli Lilly and Company
Sep 16, 2025
Maintains: Overweight
Price Target: $1,100 → $1,050
Current: $966.64
Upside: +8.62%
Amneal Pharmaceuticals
Sep 16, 2025
Maintains: Overweight
Price Target: $12 → $14
Current: $11.48
Upside: +21.95%
Regeneron Pharmaceuticals
Jun 9, 2025
Maintains: Overweight
Price Target: $950 → $800
Current: $654.74
Upside: +22.19%
May 5, 2025
Maintains: Neutral
Price Target: $185 → $175
Current: $156.26
Upside: +11.99%
Sep 6, 2024
Downgrades: Underweight
Price Target: $18 → $20
Current: $7.71
Upside: +159.40%
Feb 20, 2024
Maintains: Overweight
Price Target: $45 → $42
Current: $38.54
Upside: +8.98%
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $323.66
Upside: -16.58%
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $24.39
Upside: +39.40%
Feb 23, 2023
Maintains: Overweight
Price Target: $120 → $125
Current: $86.75
Upside: +44.09%
Nov 15, 2022
Maintains: Neutral
Price Target: $13 → $14
Current: $10.17
Upside: +37.66%
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $1.26
Upside: +773.02%
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $6.40
Upside: -
Oct 16, 2020
Maintains: Overweight
Price Target: $74 → $78
Current: $47.26
Upside: +65.04%
May 27, 2020
Maintains: Overweight
Price Target: $700 → $950
Current: $0.73
Upside: +129,858.96%
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $1.35
Upside: -
Nov 2, 2018
Maintains: Neutral
Price Target: $45 → $50
Current: $23.07
Upside: +116.73%